A clinical trial of Equecabtagene-autoleucel
Latest Information Update: 16 Aug 2024
At a glance
- Drugs Equecabtagene autoleucel (Primary)
- Indications Lupus nephritis; Systemic lupus erythematosus
- Focus Adverse reactions
Most Recent Events
- 16 Aug 2024 New trial record
- 12 Aug 2024 According to a IASO Bio media release, the company has received the investigational new drug (IND) application approval for (Equecabtagene Autoleucel by the U.S. FDA.